Check the time stamp on this data. Updated AI-Generated Signals for Catalyst Pharmaceuticals Inc. (CPRX) available here: CPRX ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

This was the stock's second consecutive day of losses.

Truist Financial analyst Joon Lee maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today. The company’s shares closed ...

StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...

(CPRX) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid price increase over a ...

View Catalyst Pharmaceuticals, Inc. (CPRX) current and estimated P/E ratio data provided by Seeking Alpha.